OncoMatch/Clinical Trials/NCT02584244
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
Is NCT02584244 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including LUM015 and LUM 2.6 Imaging Device for colorectal cancer.
Treatment: LUM015 · LUM 2.6 Imaging Device — The overall goal of this feasibility study is to assess the initial safety and efficacy of LUM015 in ex vivo far-red imaging of colorectal, pancreatic, and esophageal cancers (adenocarcinoma) using the LUM Imaging System.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Colorectal Cancer
Pancreatic Cancer
Esophageal Carcinoma
Gastric Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: investigational drug
Subjects who have taken an investigational drug within 30 days of enrollment
Lab requirements
Blood counts
Leukocytes >= 3,000/mcL; Absolute neutrophil count >= 1,500/mcL; Platelets >= 100,000/mcL
Kidney function
Creatinine within normal institutional limits or creatinine clearance >= 60 mL/min/1.73 m2 for subjects with creatinine levels above institutional normal
Liver function
total bilirubin within normal institutional limits (except in cases of malignant biliary obstruction); AST (SGOT)/ALT (SGPT) <= 2.5 X institutional upper limit of normal (<= 5 x ULN in cases of malignant biliary obstruction)
Cardiac function
QTc interval <= 480ms
Subjects must have normal organ and marrow function as defined below: Leukocytes >= 3,000/mcL; Absolute neutrophil count >= 1,500/mcL; Platelets >= 100,000/mcL; total bilirubin within normal institutional limits (except in cases of malignant biliary obstruction); AST (SGOT)/ALT (SGPT) <= 2.5 X institutional upper limit of normal (<= 5 x ULN in cases of malignant biliary obstruction); Creatinine within normal institutional limits or creatinine clearance >= 60 mL/min/1.73 m2 for subjects with creatinine levels above institutional normal. Subjects with QTc interval > 480ms [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Massachusetts General Hospital · Boston, Massachusetts
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT02584244 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior investigational drug disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages